A5005806121- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Cancer Mechanisms and Therapy
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Hepatitis C virus research
- Renal cell carcinoma treatment
- Hepatitis B Virus Studies
- Nutrition and Health in Aging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Hypoxia, and Metabolism
- Organ Transplantation Techniques and Outcomes
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Drug Transport and Resistance Mechanisms
- Liver physiology and pathology
- MicroRNA in disease regulation
- Radiopharmaceutical Chemistry and Applications
- Urticaria and Related Conditions
- Lung Cancer Research Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Cancer Diagnosis and Treatment
- Bone health and treatments
- Liver Diseases and Immunity
Hiroshima University
2021-2024
Hiroshima University Hospital
2021-2024
Weatherford College
2021
<b><i>Introduction:</i></b> We evaluated the efficacy and safety of lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for patients (<i>n</i> = 88) with intermediate-stage hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> Eighty-eight who obtained tumor control by LEN treatment were analyzed; 30 received followed TACE (LEN-TACE therapy), 58 monotherapy. Propensity score matching was performed,...
The aim of this study was to investigate the early tumor response and safety atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice. Forty Child-Pugh class A liver function eastern cooperative oncology group performance status 0 or 1 were enrolled. objective rate (ORR) at six weeks after start treatment, changes α-fetoprotein (AFP) des-γ-carboxyprothrombin, incidence adverse events (AEs), albumin-bilirubin (ALBI) score serum ammonia...
Overall survival of patients with advanced hepatocellular carcinoma (HCC) Vp4 (tumor thrombosis the main trunk or bilobar portal vein) is extremely poor.The purpose this study to clarify prognosis hepatic arterial infusion chemotherapy (HAIC) combined radiation therapy (RT) for HCC and analyze factors that contribute prognosis.In retrospective cohort study, 51 who were treated HAIC RT vein tumor met following criteria enrolled: (i) Vp4; (ii) Child-Pugh score 5-7; (iii) Eastern Cooperative...
The efficacy and safety of immune-checkpoint inhibitors (ICI) for the treatment unresectable hepatocellular carcinoma are known. We explored ICI rechallenges with direct switching from 1 regimen to another. This retrospective study included 16 patients who received atezolizumab-bevacizumab (Atezo+Bev) durvalumab-tremelimumab (Dur+Tre) as first-line second-line combination therapy, respectively, at Hiroshima University Hospital. radiological response adverse event were evaluated in all...
Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is currently positioned as the first-line for unresectable hepatocellular carcinoma (u-HCC). It may be difficult to decide whether continue this treatment if radiological response assessed stable disease (SD). Therefore, relationship between and prognosis was analyzed. A total of 109 patients with u-HCC Child-Pugh Score 5-7 received treatment. Radiological using Response Evaluation Criteria in Solid Tumors (RECIST) modified...
A total of 137 HCC patients treated with atezolizumab plus bevacizumab from October 2020 to September 2022 were enrolled. The median overall survival (OS) and progression-free (PFS) the beginning 21.1 months (range, 18.8 months–not reached) 10.5 8.2–12.1 months), respectively. Fifty diagnosed progressive disease after bevacizumab. Of this group, 24 administered lenvatinib, OS PFS lenvatinib 15.3 4.0 2.5–6.4 objective response rates based on evaluation criteria in solid tumors (RECISTs)...
The association between radiological response and overall survival (OS) was retrospectively evaluated in patients treated with lenvatinib as a first-line systemic treatment for unresectable hepatocellular carcinoma. A total of 182 Child-Pugh class liver function an Eastern Cooperative Oncology Group performance status zero or one were enrolled. Radiological evaluation performed using Response Evaluation Criteria Solid Tumors (RECIST) modified (mRECIST). Initial confirmed significant...
Abstract Aim Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first‐line for unresectable hepatocellular carcinoma (u‐HCC). Serious adverse events (AEs), including rupture of esophagogastric varices, have been seen during treatment. Therefore, relationships efficacy, safety, and portal hypertension (PH) were analyzed. Methods A total 146 patients with u‐HCC Child‐Pugh Scores 5–7 received Atezo Beva. Prophylactic treatment varices was performed risk before start...
<b><i>Introduction:</i></b> Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic HCC, aim identifying prognostic factors survival. <b><i>Methods:</i></b> total 825 advanced and B Sor, Len Atezo Bev therapy. Liver function was assessed...
Proteinuria is one of the adverse events atezolizumab plus bevacizumab combination therapy (Atezo + Bev) and can cause interruption in use Bev. However, risk factors for proteinuria patients with hepatocellular carcinoma (HCC) who are receiving Atezo Bev have not yet been investigated. The aim this study was to identify early onset unresectable HCC.Sixty-four Child-Pugh scores 5-7, an Eastern Cooperative Oncology Group performance status 0 or 1, low level (1+ less on a dipstick test urine...
Introduction: Measurements of body composition, such as the skeletal muscle index (SMI), are useful for predicting prognosis in hepatocellular carcinoma (HCC). This study aimed to analyze relationship between changes during therapy with atezolizumab plus bevacizumab (Atezo + Beva) or lenvatinib (Len) and association SMI prognosis. Methods: Patients advanced HCC Child-Pugh A status received Atezo Beva Len first-line systemic chemotherapy. We assessed composition obtained by bioelectrical...
Abstract Rationale: Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved the treatment unresectable HCC, but there few reports on failure treatment. Here, we present a case HCC with adrenal metastasis that eventually operated after lenvatinib (LEN) followed failed bevacizumab. Patient concerns: A 68-year-old man diagnosed non-alcoholic steatohepatitis-based metastasis....
The aim of this study was to investigate the relationship between body composition before lenvatinib treatment and prognosis in patients with hepatocellular carcinoma (HCC). We also assessed rate change after prognosis.
The present study retrospectively evaluated the efficacy of stereotactic body radiation therapy (SBRT), including repeated SBRT, for hepatocellular carcinoma. Participants comprised 220 HCC patients treated with SBRT in Hiroshima University Hospital between December 2008 and 2021. Median overall survival (OS) disease-free were 52 months (range, 45–64 months) 17 14–23 months), respectively. 5-year local tumor recurrence rate was 3.4% (95% confidence interval (CI), 1.3–6.9%). Fifty-three...
Transarterial chemoembolization (TACE) has been the standard treatment for intermediate-stage, unresectable hepatocellular carcinoma (u-HCC). However, with recent advances in systemic therapy and emergence of concept TACE-refractory or -unsuitable, effectiveness therapy, as well TACE, demonstrated patients judged to be -unsuitable. In this study, efficacy lenvatinib its combination TACE after was investigated 140 intermediate-stage u-HCC treated mainly because being Median overall survival...
The clinical outcome of ramucirumab in multi-molecular targeted agent (MTA) sequential therapy for unresectable hepatocellular carcinoma (u-HCC) was assessed comparison with that prior tyrosine kinase inhibitor (TKI) therapy.Sixteen patients who received as part multi-MTA u-HCC were enrolled a retrospective, cohort study. Ramucirumab started 2nd line 7 patients, 3rd 5 and 4th 4 patients.The overall response rate 6.3%, the disease control (DCR) 50.0%, median progression-free survival 2.0...
A total of 137 HCC patients treated with atezolizumab plus bevacizumab from October 2020 to September 2022 were enrolled. The median overall survival (OS) and progression-free (PFS) the beginning was 21.1 months (range, 18.8 months-not reached) 10.5 8.2‒12.1 months), respectively. Fifty diagnosed progressive disease after bevacizumab. Of this group, 24 administered lenvatinib, OS PFS lenvatinib 15.3 10.3 4.0 2.5‒6.4 objective response rates based on evaluation criteria in solid tumors...
Balloon-occluded retrograde transvenous obliteration (BRTO) is a treatment option for patients with gastric varices (GVs). This study aimed to clarify the clinical significance of portal hypertension estimated by hepatic venous pressure gradient (HVPG), subsequent exacerbation esophageal (EVs), and prognosis who underwent BRTO GVs.Thirty-six GVs treated were enrolled in this study, their HVPG was measured before (pre-HVPG) on day after (post-HVPG). After BRTO, followed-up median interval...
Abstract Background Metabolic dysfunction-associated fatty liver disease (MAFLD) represents a new classification system for disease. In this study, we investigated the clinical characteristics of patients with MAFLD-hepatocellular carcinoma (HCC) in comparison those nonalcoholic (NAFLD) and considered validity challenges criteria. Methods This study included 237 untreated non-B, non-C HCC hepatic steatosis. We examined profile laboratory findings MAFLD-HCC NAFLD-HCC. also classified...
PURPOSE Postsustained virologic response (SVR) screening following clinical guidelines does not address individual risk of hepatocellular carcinoma (HCC). Our aim is to provide tailored for patients using machine learning predict HCC incidence after SVR. METHODS Using data from 1,028 SVR patients, we developed an prediction model a random survival forest (RSF). Model performance was assessed Harrel's c-index and validated in independent cohort 737 patients. Shapley additive explanation...
<b><i>Introduction:</i></b> This study compared clinical outcomes of 2nd- and 3rd-line regorafenib in patients with unresectable hepatocellular carcinoma. <b><i>Methods:</i></b> In this retrospective cohort study, 48 were treated for Thirty-five 13 initiated on therapy, respectively. We assessed the responses to safety therapy. <b><i>Results:</i></b> There no statistically significant differences characteristics at start...
Benign recurrent intrahepatic cholestasis (BRIC) is a group of genetically heterogeneous autosomal recessive liver disorders characterized by episodes jaundice and pruritus. BRIC divided into two groups, type 1 (BRIC1) 2 (BRIC2), caused mutations in the ATP8B1 ABCB11 genes. We show that novel nonsense (c.2989G>A, c.1547T>A) are cause BRIC1. A 16-year-old girl presented with severe jaundice. Acute chronic diseases infectious (hepatitis virus), metabolic, autoimmune etiologies were excluded....
Patients with hepatocellular carcinoma (HCC) and macrovascular invasion (MVI) who receive systemic chemotherapy have a poor prognosis. This study aimed to determine if one-shot cisplatin (CDDP) via hepatic arterial infusion (HAI) combined radiation therapy (RT) prior could improve the outcomes of these patients.This consisted 32 HCC patients following eligibility criteria: (i) portal vein 3/4 and/or 2/3; (ii) received CDDP HAI; (iii) RT for MVI, (iv) Child-Pugh score ≤ 7; (v) an Eastern...